5,818 Shares in Celcuity, Inc. $CELC Bought by Simplicity Wealth LLC

Simplicity Wealth LLC bought a new position in shares of Celcuity, Inc. (NASDAQ:CELC) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,818 shares of the company’s stock, valued at approximately $580,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ogorek Anthony Joseph NY ADV bought a new position in Celcuity during the third quarter worth $27,000. US Bancorp DE boosted its stake in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after buying an additional 1,167 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Celcuity by 211.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after buying an additional 3,766 shares during the last quarter. Finally, Versant Capital Management Inc grew its holdings in shares of Celcuity by 611.2% during the third quarter. Versant Capital Management Inc now owns 1,593 shares of the company’s stock valued at $79,000 after buying an additional 1,369 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Up 3.5%

Shares of NASDAQ CELC opened at $125.65 on Friday. The stock has a market capitalization of $6.07 billion, a P/E ratio of -33.15 and a beta of 0.41. The company has a 50-day moving average price of $114.53 and a 200-day moving average price of $101.86. Celcuity, Inc. has a 1 year low of $9.51 and a 1 year high of $129.09. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. On average, equities research analysts forecast that Celcuity, Inc. will post -3.97 EPS for the current fiscal year.

Insider Buying and Selling at Celcuity

In related news, Director Richard E. Buller sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the transaction, the director directly owned 6,760 shares of the company’s stock, valued at $745,425.20. This trade represents a 30.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on CELC shares. Stifel Nicolaus lifted their price objective on shares of Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Citizens Jmp started coverage on shares of Celcuity in a report on Monday, April 27th. They set a “market outperform” rating and a $150.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $122.00 price objective on shares of Celcuity in a report on Thursday, March 26th. Wolfe Research reiterated an “outperform” rating and set a $110.00 price objective on shares of Celcuity in a report on Thursday, March 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Monday, April 20th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $114.33.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.